Therapy News and Research

RSS

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

FibroGen, Inc. (FibroGen) announced today the presentation of clinical data at the American Thoracic Society (ATS) International Conference supporting the safety and efficacy of FG-3019 in patients with idiopathic pulmonary fibrosis (IPF), a debilitating and life-threatening lung disease for which there is currently no approved therapy in the United States.

19 May 2014

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) today announced that results from a real-life, retrospective, observational study of QVAR- will be presented at the American Thoracic Society (ATS) 2014 International Conference in San Diego on May 18, 2014.

19 May 2014

Low risk prostate cancer not always low risk

More and more men who believe they have low-risk prostate cancers are opting for active surveillance, forgoing treatment and monitoring the cancer closely with prostate-specific antigen (PSA) tests, digital rectal exams and ultrasounds at regular intervals to see if their tumors are growing. Nearly 400 men are now enrolled in the UCLA Active Surveillance program, the largest in Southern California.

19 May 2014

Study shows commonly used statin drug does not reduce acute COPD exacerbations

A statin drug commonly used to lower cholesterol is not effective in reducing the number and severity of flare ups from chronic obstructive pulmonary disease (COPD), according to the results of a large multicenter clinical trial designed and directed by Gerard J. Criner, MD, Director of Pulmonary and Critical Care Medicine at Temple University Hospital in Philadelphia, PA.

19 May 2014

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Bio-Path Holdings, Inc., a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced operational and financial results for the first quarter ended March 31, 2014.

17 May 2014

$Fracture liaison service reduces risk of fragility fractures in older adults$

Fracture liaison service reduces risk of fragility fractures in older adults

Studies have shown that anyone age 50 or older who suffers a fragility fracture – a bone break sustained in a fall from a standing height or less – is two to five times more likely to experience a second fracture than someone who hasn't had one. The odds that a person who's suffered two such fractures will have a third are even higher.

17 May 2014

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Janssen-Cilag International NV today announced that its next generation protease inhibitor (PI) OLYSIOTM (simeprevir) has been granted marketing authorisation by the European Commission (EC) for the treatment of adults with genotype 1 and 4 chronic hepatitis C (CHC), in combination with other medicinal products.

16 May 2014

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces preliminary top-line results from the Phase II/III pivotal clinical trial in Europe and Canada of the Company's proprietary inhaled Alpha-1 Antitrypsin (AAT) therapy for the treatment of Alpha-1 Antitrypsin Deficiency (AATD or inherited emphysema).

16 May 2014

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

Bristol-Myers Squibb Company today announced results from a Phase 2 and a Phase 1b study of its investigational PD-1 immune checkpoint inhibitor nivolumab in patients with advanced or metastatic renal cell carcinoma (RCC), commonly known as kidney cancer.

16 May 2014

MD Anderson Cancer Center, Concord Medical sign consulting agreement for cancer hospital projects

Concord Medical Services Holdings Limited ("Concord Medical" or the "Company"), a leading specialty hospital management solution provider and operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced it has engaged The University of Texas MD Anderson Cancer Center ("MD Anderson") as a consultant for its cancer hospital projects under planning in Shanghai and Beijing.

16 May 2014

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

Bristol-Myers Squibb Company today announced updated survival data from the advanced melanoma cohort of Phase 1b study.

16 May 2014

State highlights: 700 nurses needed for health care help in Calif. county; Missouri abortion wait period; nursing home funding in Maine

A selection of health policy stories from California, Missouri, Maine, Michigan, North Carolina, Texas and Georgia.

16 May 2014

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Telormedix, a clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, today announced that it has successfully completed a Phase II trial, conducted under an IND, of Vesimune (TMX-101) in CIS (carcinoma in situ) of the bladder.

16 May 2014

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

A vaccine or other therapy directed at a single site on a surface protein of HIV could in principle neutralize nearly all strains of the virus—thanks to the diversity of targets the site presents to the human immune system.

16 May 2014

Anticoagulation therapy with low-dose aspirin can be used with new generation mechanical heart valve

Less aggressive anticoagulation therapy, combined with low-dose aspirin, can be used safely in conjunction with a newer generation mechanical heart valve.

16 May 2014

Lung cancer screening guidelines could cost Medicare billions

A study of Medicare beneficiaries with a history of heavy smoking found that new lung cancer screening guidelines would likely double the proportion of lung cancers found at an early stage, but at a steep cost of more than $9 billion over five years.

16 May 2014

Researchers develop potential route to new therapies for treatment of Parkinson's disease

A biologist and a psychologist at the University of York have joined forces with a drug discovery group at Lundbeck in Denmark to develop a potential route to new therapies for the treatment of Parkinson's Disease (PD).

16 May 2014

MetLife announces recipients of 2014 MetLife Foundation Awards for Medical Research

MetLife Foundation today announced the recipients of the 2014 MetLife Foundation Awards for Medical Research.

16 May 2014

Nanogel heals burn wounds faster

Researchers at the Institute of Bioengineering and Nanotechnology have developed a nanogel that can accelerate the healing of burn wounds to minimize the risk of infection and scarring. The technology is based on IBN’s proprietary self-assembling ultrashort peptide technology, which are short sequences of amino acids.

16 May 2014

Researchers test genomic sequencing for women with triple negative breast cancer

Indiana University cancer researchers are testing whether therapy incorporating advanced genomic technology will provide better outcomes than current treatments for those with an aggressive form of breast cancer.

15 May 2014

Therapy News and Research

FibroGen’s Phase 2a study supports safety and efficacy of FG-3019 in IPF patients

TEVA presents results from real-life, observational study of QVAR at ATS 2014 International Conference

Low risk prostate cancer not always low risk

Study shows commonly used statin drug does not reduce acute COPD exacerbations

Bio-Path Holdings reports net loss of $504,876 for first quarter 2014

Fracture liaison service reduces risk of fragility fractures in older adults

OLYSIO (simeprevir) receives EC marketing authorisation for treatment of genotype 1 and 4 CHC

Kamada announces top-line results from Phase II/III trial for treatment of inherited emphysema

Bristol-Myers Squibb announces study results of nivolumab drug in patients with renal cell carcinoma

MD Anderson Cancer Center, Concord Medical sign consulting agreement for cancer hospital projects

Bristol-Myers Squibb reports updated survival data from Phase 1b study of advanced melanoma

State highlights: 700 nurses needed for health care help in Calif. county; Missouri abortion wait period; nursing home funding in Maine

Telormedix completes Phase II trial of Vesimune in CIS of the bladder

Study led by TSRI scientists likely to influence future designs for HIV vaccines, antibody-based therapies

Anticoagulation therapy with low-dose aspirin can be used with new generation mechanical heart valve

Lung cancer screening guidelines could cost Medicare billions

Researchers develop potential route to new therapies for treatment of Parkinson's disease

MetLife announces recipients of 2014 MetLife Foundation Awards for Medical Research

Nanogel heals burn wounds faster

Researchers test genomic sequencing for women with triple negative breast cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News